Vancomycin and Hearing Loss: Causes and Prevention

Vancomycin, one of the most important antibiotics for treating serious drug-resistant infections, carries a recognized but relatively uncommon risk of hearing loss. The risk is real enough that clinicians monitor for it, yet studies consistently find that most patients complete treatment without measurable damage to their hearing. What makes vancomycin-related hearing loss tricky is that it tends to start in frequency ranges you do not normally notice, and the people most vulnerable are not always the ones you would expect.

How Common Is Vancomycin-Related Hearing Loss

Estimates of how often vancomycin causes hearing loss vary depending on how carefully researchers look for it. In a study of 89 patients who received vancomycin for an average of about four weeks and then had formal hearing tests, roughly 12% showed new high-frequency hearing loss.¹ A separate study that followed patients on long-term vancomycin therapy found that about 8% experienced some worsening of hearing from their baseline audiogram, though only a fraction of those developed moderate-to-severe loss.²

Those numbers are not trivial, but they are far lower than the ototoxicity rates seen with some other drug classes. The range of roughly 8% to 12% in monitored studies likely reflects real-world risk reasonably well, though many milder cases probably go undetected when patients are not given hearing tests during treatment. If no one checks your hearing before and after a course of vancomycin, a subtle shift in your ability to hear very high-pitched sounds could easily pass unnoticed.

Why High Frequencies Get Hit First

Vancomycin-related hearing loss does not suddenly muffle conversation or make music sound different. It starts in the highest frequency ranges, often above what standard hearing tests measure. Research using ultra-high-frequency audiometry, which tests up to 20 kHz instead of the usual 8 kHz cutoff, has shown that ototoxic damage typically begins at these upper frequencies and then creeps downward into the speech-relevant range if drug exposure continues.³

This pattern matters practically. By the time a patient notices difficulty hearing voices or environmental sounds, the damage may already be extensive. The high-frequency-first progression is actually a window of opportunity: if clinicians test at those upper ranges regularly, they can catch early signs of trouble and adjust treatment before the loss spreads to frequencies that affect daily communication.

Age and the Sharp Divide in Risk

One of the clearest findings in vancomycin ototoxicity research is the role of age, and the effect is surprisingly sharp. In the study that found 12% overall hearing loss, researchers used statistical modeling to look for the most meaningful dividing line. Among patients younger than 53, the rate of high-frequency hearing loss was 0%. Among those older than 53, it jumped to 19%.¹ That is not a gentle slope. It suggests that aging ears, which are already losing some of their resilience at the cellular level, are substantially more vulnerable to additional chemical insult.

This finding has practical implications for how vancomycin is prescribed to older patients. It does not mean avoiding the drug entirely when it is needed, since vancomycin is often the best or only option for certain infections. But it does argue for closer hearing monitoring in older adults, and for being especially careful about dose and duration when alternatives exist.

What About Babies and Newborns

Premature and very-low-birthweight infants often receive vancomycin in neonatal intensive care units because they are at high risk for serious bacterial infections. The question of whether the drug harms their developing auditory systems has produced mixed results, which is itself informative.

A large study of a German neonatal network found that vancomycin exposure was independently associated with abnormal hearing tests at discharge, though the effect size was modest. More strikingly, the risk appeared dose-dependent: infants who received a cumulative dose above the upper quartile had roughly twice the odds of failing their hearing test compared to those who received less.⁴ A scoping review looking across multiple neonatal studies confirmed this pattern, with two of four studies reporting a dose-dependent relationship between vancomycin and infant hearing loss.⁵

Yet other research has found no connection. One study examining newborn hearing screening results concluded that vancomycin exposure, whether measured by treatment duration, total dose, or blood levels, was not linked to failing automated auditory brainstem response screening.⁶ The disagreement likely comes down to differences in how hearing was tested and how long infants were followed. Automated screening at discharge can miss subtle damage that formal audiometry picks up later. The weight of evidence suggests there is a dose-dependent risk in neonates, but it is not overwhelming, and lower doses appear to carry little measurable danger.

Blood Levels, Kidney Function, and the Dose Connection

The single most consistent theme in vancomycin ototoxicity research is the connection between drug blood levels and hearing damage. Ototoxicity is related to high serum concentrations of vancomycin, and anything that drives those concentrations up increases the hazard.⁷

Kidney function plays a central role here. Vancomycin is cleared from the body primarily through the kidneys. When kidney function is impaired, the drug accumulates in the blood, reaching concentrations that can damage the delicate hair cells of the inner ear. This is why patients with kidney disease are at elevated risk, and why even oral vancomycin, which is usually considered to stay in the gut, can occasionally cause hearing problems: in patients with inflamed or damaged intestinal walls and poor kidney function, enough of the drug can be absorbed into the bloodstream to reach potentially toxic levels.⁷

Interestingly, the long-term study that found 8% hearing worsening did not find a clear association between elevated trough levels or daily doses above 4 grams and worsening audiograms in its analysis.² Meanwhile, the study of older versus younger patients found that the average peak trough levels were similar between patients who did and did not develop hearing loss.¹ This makes the picture muddier than a simple “higher blood levels equal more damage” story. Individual susceptibility clearly matters, and some people’s ears tolerate the same blood levels that hurt others. Age, as discussed above, appears to be a major part of that susceptibility.

What Happens After Overdose

Accidental vancomycin overdoses provide a kind of natural experiment, and the results are more reassuring than you might expect. A case series of six pediatric patients who all reached estimated peak blood levels above 80 mg/L, with five exceeding 150 mg/L (normal therapeutic troughs are usually kept under 20 mg/L), found that none developed prolonged hearing loss. One child experienced transient ototoxicity that resolved, and all six had temporary kidney dysfunction that also recovered.⁸

This is a small sample, and all subjects were young (four were under three months old), which may have worked in their favor given the age-risk pattern noted earlier. Still, the fact that even dramatically elevated blood levels did not cause permanent hearing loss in these children challenges the assumption that any single toxic spike will inevitably damage the ears. Chronic exposure and cumulative dose may be more dangerous than brief, severe peaks, at least in some populations.

Preventing Hearing Loss During Treatment

The main strategy for preventing vancomycin-related hearing loss is careful drug monitoring and dose adjustment. Current clinical guidelines recommend using area-under-the-curve (AUC) based therapeutic drug monitoring rather than relying solely on trough levels. AUC monitoring gives a more complete picture of how much drug a patient is actually exposed to over a full dosing cycle, rather than just how low the level drops before the next dose. Health systems have been implementing this approach, aiming to keep drug exposure in the effective range for fighting infection while minimizing toxicity risks.⁹

Beyond blood-level monitoring, baseline hearing tests before starting vancomycin and repeat testing during treatment can catch early damage. As noted earlier, testing in the ultra-high-frequency range (above 8 kHz) is more sensitive than standard audiometry for detecting the earliest signs of ototoxicity.³ In practice, though, ultra-high-frequency testing is not available everywhere, and many patients receiving vancomycin in hospitals never get formal audiometry at all. Patients who know they will be on the drug for more than a few days, especially older adults, should ask about hearing monitoring.

Other practical prevention measures include:

Kidney function checks: Since impaired kidneys drive up vancomycin levels, regular monitoring of kidney function allows dose adjustments before blood levels climb dangerously high.
Minimizing concurrent ototoxins: Aminoglycoside antibiotics like gentamicin and tobramycin have their own well-established ototoxic potential. Combining them with vancomycin is sometimes necessary, but the combination raises the risk beyond either drug alone. When possible, clinicians try to avoid doubling up on ototoxic medications.
Shortest effective course: Using vancomycin only as long as clinically needed, rather than extending treatment “just in case,” reduces cumulative exposure. The dose-dependent findings in neonates reinforce this principle.

N-Acetylcysteine as a Protective Agent

One of the more promising approaches to protecting hearing during ototoxic drug treatment involves N-acetylcysteine (NAC), the same compound used as a supplement and as an antidote for acetaminophen overdose. NAC is a potent antioxidant, and since drug-induced ototoxicity involves oxidative damage to the hair cells of the inner ear, the logic behind using it as a shield is straightforward.

A study of dialysis patients being treated for peritonitis with vancomycin or gentamicin found that those who received NAC alongside their antibiotic had measurably better hearing outcomes. NAC protected low-frequency hearing functions, and patients taking it showed improvement in high-frequency hearing at one and four weeks compared to their starting point. Patients in the control group who did not receive NAC saw their high-frequency hearing worsen over the same period.¹⁰

This is encouraging, but the evidence base is still thin. The study was conducted in a specific population, dialysis patients with peritonitis, and the sample sizes in otoprotection research generally remain small. NAC is not yet a standard part of vancomycin treatment protocols, and more research is needed to determine optimal dosing and timing. Still, it is one of the few interventions that has shown a measurable protective effect, and its safety profile is well established from decades of use in other medical contexts.

When Clinicians Consider Alternatives

For patients at high risk of vancomycin side effects, or those who develop signs of toxicity during treatment, several alternative antibiotics can treat the same infections. The choice depends on the specific bug being fought and the patient’s clinical situation.

Teicoplanin belongs to the same antibiotic class as vancomycin but has a longer half-life and more flexible dosing. It can be given as a quick intravenous push or even intramuscularly, and both ototoxicity and kidney toxicity are relatively uncommon with it.¹¹ Teicoplanin is widely used in Europe and other regions, though it has not been approved in the United States, which limits its availability for American patients.

Linezolid is another option, particularly for methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infections, one of the main reasons vancomycin gets prescribed. A systematic review and meta-analysis comparing linezolid to vancomycin and other alternatives for MRSA bacteremia found comparable effectiveness and no difference in adverse events.¹² Linezolid has its own side effects, including blood cell suppression during prolonged use, so it is not a universally safer choice. But for patients already showing signs of vancomycin ototoxicity or kidney damage, switching to linezolid or daptomycin can preserve hearing while still fighting the infection effectively.

The Oral Vancomycin Misconception

Many people, and even some healthcare providers, assume that oral vancomycin is free from systemic side effects because the drug is not supposed to be absorbed from the gut. Oral vancomycin is prescribed primarily for Clostridioides difficile colitis, and in patients with a healthy intestinal lining, virtually none of the drug reaches the bloodstream. But the assumption breaks down in patients whose gut barrier is compromised by inflammation, surgery, or disease.

Case reports have documented patients who developed ototoxicity from oral vancomycin when they also had impaired kidney function. In these patients, enough vancomycin crossed from the inflamed gut into the blood to reach serum levels that normally only occur with intravenous dosing.⁷ The combination of gut inflammation allowing absorption and kidneys unable to clear the drug creates a double hit that can push blood levels into the danger zone. Patients with kidney disease who are prescribed oral vancomycin should be aware of this possibility, even though it remains uncommon.

Is Vancomycin-Related Hearing Loss Reversible

The reversibility question does not have a clean answer, and that uncertainty reflects the limited data available. In the pediatric overdose cases, the one child who experienced ototoxicity recovered fully, suggesting that at least some acute damage can reverse.⁸ Case reports in the literature describe ototoxicity as potentially either transient or permanent.⁷

The biology of the inner ear helps explain this ambiguity. The hair cells in the cochlea, which convert sound vibrations into nerve signals, do not regenerate in humans once they are destroyed. If vancomycin exposure causes permanent hair cell death, the hearing loss is permanent. But if the drug causes temporary dysfunction, perhaps through disruption of the electrochemical environment within the inner ear rather than outright cell death, recovery is possible once the drug clears the system. The trouble is that clinicians cannot easily tell which type of injury has occurred while the patient is still on the drug. Early detection and prompt dose adjustment or drug discontinuation give the best chance of catching damage while it is still in the reversible stage.

Vancomycin Compared to Aminoglycosides

Vancomycin often gets lumped together with aminoglycoside antibiotics like gentamicin and tobramycin in discussions of drug-related hearing loss, but the comparison is not quite fair. Aminoglycosides have a much more established and aggressive ototoxicity profile. They are well known to cause permanent, irreversible hearing loss and vestibular damage (balance problems), and the risk is high enough that their use is carefully restricted even though they remain essential for certain infections.

Vancomycin’s ototoxic effects, by comparison, appear milder on average and are more clearly linked to specific risk factors like advanced age, kidney impairment, and high blood levels. The combination of vancomycin and an aminoglycoside, however, is where risk escalates. Clinicians prescribe this combination when facing life-threatening infections like endocarditis, and monitoring hearing and kidney function becomes especially important in those situations. The ultra-high-frequency monitoring approach described earlier was originally developed to track ototoxicity from both drug classes in dialysis patients being treated with vancomycin or gentamicin.³

For patients and families trying to weigh risks, the key distinction is this: vancomycin-related hearing loss is a possible side effect worth monitoring for, while aminoglycoside-related hearing loss is a well-documented hazard that clinicians actively strategize to minimize. If you are receiving vancomycin alone, the odds are in your favor. If you are receiving both, ask your care team about hearing monitoring and whether the combination remains necessary as your infection responds to treatment.